Oncodoctor

About Mikhail Blagosklonny Biography: Mikhail (Misha) V. Blagosklonny graduated with an MD and PhD from First Pavlov State Medical University of St. Petersburg, Russia. Dr. Mikhail V. Blagosklonny subsequently relocated to the United States, where he was awarded the prestigious Fogarty Fellowship from the National Institutes of Health. During his fellowship in Leonard Neckers’ laboratory at the National Cancer Institute (NCI), he was a co-author of 18 publications on diverse biomedical topics, including targeting HSP90, p53, Bcl2, Erb2, and Raf-1. He also was the last author on a clinical phase I/II trial paper.  After authoring seven papers during a brief yet productive senior research fellowship in the El-Deiry Cancer Research Lab at the University of Pennsylvania, Dr. Blagosklonny returned to NCI to work with Tito Fojo. Together, they published 26 papers. In addition, Dr. Blagosklonny published dozens of experimental research articles and theoretical papers as sole author. These...

Misha Blagosklonny of Oncotarget Welcome to mishablagosklonny.com. Misha Blagosklonny is one of the Editor-in-Chiefs at Oncotarget. The Editorial board at Oncotarget includes the most prominent cancer researchers in the world. In fact, Misha Blagosklonny is proud to say that during a short history of Oncotarget many Editorial Board members have become members of the National Academy of Sciences USA, won Lasker, Nobel and other prestigious awards. The story of Mikhail (Misha) V. Blagosklonny started when he graduated with an MD and PhD from First Pavlov State Medical University of St. Petersburg, Russia. Dr. Misha Blagosklonny of Oncotarget then moved to the United States where he became famous for contributions to  the research of cancer and aging. Everything Dr. Misha Blagosklonny of Oncotarget contributes to is to further understand the cause of cancer and find an efficient treatment. Soon,  Misha Blagosklonny and  Oncotarget will once again be a major part of the Ride ...

Altmetric Score for Oncotarget Publications Provides Vital Insight, Mikhail (Misha) Blagosklonny says When it comes to modern medicine, it’s impossible to understate the importance of accuracy. Researchers who are publishing papers on pressing issues must be held to a high standard. The problem is that research outputs can live online and be passionately discussed without ever being thoroughly vetted.  Mikhail (Misha) Blagosklonny of Oncotarget  knew that a better option had to exist. That’s why Oncotarget,  a weekly oncology-focused research journal  that was established in 2010, uses easy-to-understand Altmetric scores to shine more light. Authors and readers can now gauge publications alongside  Altmetric Article Reports , which provides “real-time feedback that contain a summary of data regarding the online engagement relating to a particular publication.” On its website, Oncotarget has released the list of publications  with the score higher than 100 ...